Abstract
It is now exactly 100 years ago (1908) that Paul Ehrlich, who is regarded as the inventor of the concept of targeted therapy, received the Nobel Prize for Medicine. His initial perception leading to this theory was derived from observations that certain substances are capable of selectively staining either tissues or microorganisms. These observations culminated in the discovery of the inorganic mercury compound arsphenamine (Salvarsan®) by Sahachiro Hata in the laboratory of Paul Ehrlich. Salvarsan® might be regarded as the first effective “targeted” treatment for syphilis at that time. Tamoxifen (Nolvadex®), an anti-estrogen, which was introduced in the early 1970s, was one of the first rationally designed targeted anti-tumour drugs. Since the 1970s a dramatic development of new molecular technologies occurred, culminating, for example, into the Human Genome Project and the public availability of various gene and protein databases, such as the Cancer Genome Anatomy Program established by the National Cancer Institute. Genomics, proteomics, structural genomics, transcriptomics, and high-throughput screening technologies for identification of targeted drugs are now available, which were almost unimaginable only a few years ago. Over 500 kinases are known of which about 250 have been cloned and are available to directly evaluate the activity of novel drug candidates. These technologies in conjunction with bio-informatic and chemical tools allow us to design novel molecules, and consequently tailor drug therapy to specific targets within tumours.
Keywords: Molecular targeted therapies, monoclonal antibodies, tyrosine kinase inhibitors, small molecules, oncology, hematology
Current Pharmaceutical Design
Title: Targeted Therapies in Solid Tumours: Pinpointing the Tumours Achilles Heel
Volume: 15 Issue: 2
Author(s): Gabriela Kornek and Edgar Selzer
Affiliation:
Keywords: Molecular targeted therapies, monoclonal antibodies, tyrosine kinase inhibitors, small molecules, oncology, hematology
Abstract: It is now exactly 100 years ago (1908) that Paul Ehrlich, who is regarded as the inventor of the concept of targeted therapy, received the Nobel Prize for Medicine. His initial perception leading to this theory was derived from observations that certain substances are capable of selectively staining either tissues or microorganisms. These observations culminated in the discovery of the inorganic mercury compound arsphenamine (Salvarsan®) by Sahachiro Hata in the laboratory of Paul Ehrlich. Salvarsan® might be regarded as the first effective “targeted” treatment for syphilis at that time. Tamoxifen (Nolvadex®), an anti-estrogen, which was introduced in the early 1970s, was one of the first rationally designed targeted anti-tumour drugs. Since the 1970s a dramatic development of new molecular technologies occurred, culminating, for example, into the Human Genome Project and the public availability of various gene and protein databases, such as the Cancer Genome Anatomy Program established by the National Cancer Institute. Genomics, proteomics, structural genomics, transcriptomics, and high-throughput screening technologies for identification of targeted drugs are now available, which were almost unimaginable only a few years ago. Over 500 kinases are known of which about 250 have been cloned and are available to directly evaluate the activity of novel drug candidates. These technologies in conjunction with bio-informatic and chemical tools allow us to design novel molecules, and consequently tailor drug therapy to specific targets within tumours.
Export Options
About this article
Cite this article as:
Kornek Gabriela and Selzer Edgar, Targeted Therapies in Solid Tumours: Pinpointing the Tumours Achilles Heel, Current Pharmaceutical Design 2009; 15 (2) . https://dx.doi.org/10.2174/138161209787002906
DOI https://dx.doi.org/10.2174/138161209787002906 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Outline of Proteins and Signaling Pathways Involved in Heart Failure
Current Protein & Peptide Science The Delivery of Personalised, Precision Medicines <i>via</i> Synthetic Proteins
Drug Delivery Letters How to Target Activated Ras Proteins: Direct Inhibition vs. Induced Mislocalization
Mini-Reviews in Medicinal Chemistry Transthyretin Deposition in Familial Amyloidotic Polyneuropathy
Current Medicinal Chemistry The Autocrine/Paracrine Loop After Myocardial Stretch: Mineralocorticoid Receptor Activation
Current Cardiology Reviews Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Antagonists in Experimental Myocarditis
Current Pharmaceutical Design Pulmonary Arterial Hypertension in HIV-infected Patients
Current Hypertension Reviews Clinical Applications of Cardiovascular Magnetic Resonance
Current Pharmaceutical Design Sepsis Pathophysiology and Anesthetic Consideration
Cardiovascular & Hematological Disorders-Drug Targets Exploring the Role of Gene Therapy for Neurological Disorders
Current Gene Therapy Natriuretic Peptide Family: New Aspects
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Normal Ventricular Functional Reference Parameters on Magnetic Resonance Imaging in Healthy Children
Current Medical Imaging Therapy for Dominant Inherited Diseases by Allele-Specific RNA Interference: Successes and Pitfalls
Current Gene Therapy Sympathetic Activation in Congestive Heart Failure: Evidence, Consequences and Therapeutic Implications
Current Vascular Pharmacology Diallyl Sulfide: Potential Use in Novel Therapeutic Interventions in Alcohol, Drugs, and Disease Mediated Cellular Toxicity by Targeting Cytochrome P450 2E1
Current Drug Metabolism Hydrogen Sulfide in Diabetic Complications: Focus on Molecular Mechanisms
Endocrine, Metabolic & Immune Disorders - Drug Targets QT Alterations in Psychopharmacology: Proven Candidates and Suspects
Current Drug Safety Pharmacological Interference With Protein-protein Interactions of Akinase Anchoring Proteins as a Strategy for the Treatment of Disease
Current Drug Targets Potential Therapeutic Effects of Na+/Ca2+ Exchanger Inhibition in Cardiac Diseases
Current Medicinal Chemistry Heme Oxygenase: A Target Gene for Anti-Diabetic and Obesity
Current Pharmaceutical Design